Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1370180 | Bioorganic & Medicinal Chemistry Letters | 2011 | 6 Pages |
Abstract
The design, synthesis and SAR of a novel class of valerolactam-based arylsulfonamides as potent and selective FXa inhibitors is reported. The arylsulfonamide–valerolactam scaffold was derived based on the proposed bioisosterism to the arylcyanoguanidine-caprolactam core in known FXa inhibitors. The SAR study led to compound 46 as the most potent FXa inhibitor in this series, with an IC50 of 7 nM and EC2×PT of 1.7 μM. The X-ray structure of compound 40 bound to FXa shows that the sulfonamide–valerolactam scaffold anchors the aryl group in the S1 and the novel acylcytisine pharmacophore in the S4 pockets.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Yan Shi, Stephen P. O’Connor, Doree Sitkoff, Jing Zhang, Mengxiao Shi, Sharon N. Bisaha, Ying Wang, Chi Li, Zheming Ruan, R. Michael Lawrence, Herbert E. Klei, Kevin Kish, Eddie C.-K. Liu, Steve M. Seiler, Liang Schweizer, Thomas E. Steinbacher,